SAN DIEGO, July 10, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the "Class Period"), have until Tuesday, August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit.  Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI's top executives with vi ...

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the “Class Period”), have until Tuesday, August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI’s top ...

Core Viewpoint - Tempus AI, Inc. is facing a class action lawsuit due to allegations of misleading statements and undisclosed material information during the specified Class Period, which has led to significant investor losses [1][3][4]. Group 1: Class Action Details - The class action lawsuit represents investors who purchased Tempus AI securities between August 6, 2024, and May 27, 2025, with a deadline for filing a lead plaintiff motion set for August 12, 2025 [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation regarding their legal rights and options for recovering losses [2]. Group 2: Allegations Against Tempus AI - The lawsuit alleges that Tempus AI inflated the value of certain contract agreements, many of which involved related parties and included non-binding opt-ins or were self-funded [3]. - Concerns were raised about a joint venture with SoftBank Group Corporation, which allegedly risked credibility by appearing to "round-trip" capital to artificially inflate revenue [3]. - The acquisition of Ambry Genetics Corporation is claimed to have operated under a business model reliant on aggressive and potentially unethical billing practices, exposing it to regulatory and financial risks [3]. - AstraZeneca PLC reportedly reduced its financial support to Tempus AI through a questionable "pass-through payment" structure involving a joint agreement with Pathos AI, Inc. [3]. - These issues are indicative of broader weaknesses in Tempus AI's core operations and long-term revenue outlook [3]. Group 3: Impact on Stock Price - Following the publication of a research report by Spruce Point Capital Management, LLC on May 28, 2025, which highlighted serious concerns regarding Tempus AI's management and operations, the company's stock price fell by over 19% [4].